e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 7, 2010
WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
         
Nevada   001-03305   95-3872914
         
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)
     
311 Bonnie Circle
Corona, California
   
92880
     
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report): Not applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 5.07   Submission of Matters to a Vote of Security Holders.
     On May 7, 2010, the Annual Meeting of the Stockholders of Watson Pharmaceuticals, Inc. (“the Company”) was held in Parsippany, NJ. The following directors were elected to the Company’s Board of Directors for a term of three years expiring at the Annual Meeting of Stockholders in 2013:
     
 
                                 
    For     Against     Abstain     Broker Non-Votes  
Paul M. Bisaro
    90,923,656       606,242       3,111,548       9,355,424  
Christopher W. Bodine
    91,944,566       574,887       2,121,993       9,355,424  
Michel J. Feldman
    86,308,424       2,094,404       6,238,618       9,355,424  
Fred G. Weiss
    72,703,042       1,243,396       20,695,008       9,355,424  
     
 
     In addition to voting to elect the aforementioned directors, the Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010. The results of the vote were as follows:
     
 
                         
    For     Against     Abstain  
Ratification of Appointment of PricewaterhouseCoopers LLP
    101,281,586       2,608,720       106,564  
     
 

 


 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: May 12, 2010  WATSON PHARMACEUTICALS, INC.
 
 
  By:   /s/  David A. Buchen  
    Name:   David A. Buchen  
    Title:   Senior Vice President, General Counsel and Secretary